1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
2. The Editorial Board of the Cancer Statistics in Japan. CANCER STATISTICS IN JAPAN 2017. Foundation for Promotion of Cancer Research (FPCR); 2017.
3. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.
4. 日本胃癌学会. 胃癌治療ガイドライン 医師用 2018年1月改訂 第5版. 金原出版; 2018.
5. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1–10.
6. Zhao X, Subramanian S. Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. Cancer Res. 2017;77:817–22.
7. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–67. doi:10.1056/NEJMoa1602252.
8. Robert C, Long G V., Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med. 2015;372:320–30. doi:10.1056/NEJMoa1412082.
9. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1504627.
10. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803–13. doi:10.1056/NEJMoa1510665.
11. Blank CU, Haanen JB, Ribas A, Schumacher TN. The “cancer immunogram.” Science (80- ). 2016;352:658–60. doi:10.1126/science.aaf2834.
12. Karasaki T, Nagayama K, Kuwano H, Nitadori J ichi, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. J Thorac Oncol. 2017;12:791–803. doi:10.1016/j.jtho.2017.01.005.
13. 日本胃癌学会. 胃癌取扱い規約(2010年3月改訂 [第14版]). 金原出版; 2010.
14. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–95.
15. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303. doi:10.1101/gr.107524.110.
16. Wilson RK, Mardis ER, McLellan MD, Koboldt DC, Shen D, Zhang Q, Ding L, Larson DE, Lin L, Miller CA. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22:568–76.
17. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213–9. doi:10.1038/nbt.2514.
18. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
19. Anders S, Pyl PT, Huber W. HTSeq-A Python framework to work with highthroughput sequencing data. Bioinformatics. 2015;31:166–9.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545–50. doi:10.1073/pnas.0506580102.
21. Matey-Hernandez ML, Brunak S, Izarzugaza JMG. Benchmarking the HLA typing performance of Polysolver and Optitype in 50 Danish parental trios. BMC Bioinformatics. 2018;19:1–12.
22. Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2016;4:463–71. doi:10.1158/2326-6066.CIR-15-0225.
23. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. NetMHCpan, a method for MHC class i binding prediction beyond humans. Immunogenetics. 2009;61:1–13.
24. Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K. The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. Oncoimmunology. 2017;6:e1338996. doi:10.1080/2162402X.2017.1338996.
25. Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:1–7.
26. Quinlan AR, Hall IM. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–2.
27. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. doi:10.1038/nature13480.
28. Chu J, Sadeghi S, Raymond A, Jackman SD, Nip KM, Mar R, Mohamadi H, Butterfield YS, Robertson AG, Birol I. BioBloom tools: Fast, accurate and memory-efficient host species sequence screening using bloom filters. Bioinformatics. 2014;30:3402–4.
29. Ni Huang M, McPherson JR, Cutcutache I, Teh BT, Tan P, Rozen SG. MSIseq: Software for assessing microsatellite instability from catalogs of somatic mutations. Sci Rep. 2015;5:1–10. doi:10.1038/srep13321.
30. Oh SC, Sohn BH, Cheong JH, Kim SSYSSBC, Lee JJHJEJJS, Park KC, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9. doi:10.1038/s41467-018-04179-8.
31. Lee J, Cristescu R, Kim KK-MK, Kim KK-MK, Kim ST, Park SH, Kang WK. Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget. 2017;8:66305–15.
32. Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K. Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins. Bioconjug Chem. 2015;26:2076–84
33. Sun J, Nishiyama T, Shimizu K, Kadota K. TCC: An R package for comparing tag count data with robust normalization strategies. BMC Bioinformatics. 2013;14:1. doi:10.1186/1471-2105-14-219.
34. Lamarre S, Frasse P, Zouine M, Labourdette D, Sainderichin E, Hu G, Le Berre-Anton V, Bouzayen M, Maza E. Optimization of an RNA-Seq Differential Gene Expression Analysis Depending on Biological Replicate Number and Library Size. Front Plant Sci. 2018;9 February. doi:10.3389/fpls.2018.00108.
35. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
36. Comprehensive Molecular Characterization of Gastric Adenocarcinoma Supplementary Materials.
37. Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, et al. CancerGermline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018;173:624–633.e8. doi:10.1016/j.cell.2018.03.026.
38. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7.
39. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1–6. doi:10.1016/j.coi.2015.10.009.
40. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24 October.
41. Kim ST, Cristescu R, Bass AJ, Kim K-MMK, Odegaard JI, Kim K-MMK, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–58. doi:10.1038/s41591-018-0101-z.
42. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 2014;371:2189–99. doi:10.1056/NEJMoa1406498.
43. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non – small cell lung cancer. Science (80- ). 2016;348:124.
44. Ganesh K, Massagué J. TGF-β Inhibition and Immunotherapy: Checkmate. Immunity. 2018;48:626–8.
45. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21:914–21. doi:10.1038/nm.3910.
46. Fesnak AD, June CH, Levine BL. Engineered T cells : the promise and challenges of cancer immunotherapy. Nat Publ Gr. 2016;16:566–81. doi:10.1038/nrc.2016.97.
47. Garfall AL, Maus M V., Hwang W-T, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr NDS, Bagg A, Levine BL, June CH, Stadtmauer EA. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015;373:1040–7. doi:10.1056/NEJMoa1504542.
48. Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017;28 March:xii11-xii17.
49. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–5.
50. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NFkappaB-cytokine network. Cancer Discov. 2011;1:158–69.
51. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane J-PP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136. doi:10.1038/s41467-017-01062-w.
52. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167:397–404.e9. doi:10.1016/j.cell.2016.08.069.
53. Kouidhi S, Elgaaied AB, Chouaib S. Impact of metabolism on T-cell differentiation and function and cross talk with tumor microenvironment. Front Immunol. 2017;8 MAR:1– 13.
54. Platten M, Wick W, Van Den Eynde BJ. Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res. 2012;72:5435–40.
55. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Shelley Hwang E, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67.
56. Scharping N, Delgoffe G. Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines. 2016;4:46. doi:10.3390/vaccines4040046.
57. Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance Mechanisms to ImmuneCheckpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016;44:1255–69